Morningstar

Bayer’s MEDRAD® Centargo Multi-Patient CT Injection System Now With A Wider Range of Compatible CT Contrast Agents and Presentations

Bayer today announced that its MEDRAD® Centargo multi-patient CT injector has secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) to expand the use of compatible contrast agent ...
PharmiWeb

Bayer receives FDA clearance for expanded use of MEDRAD® Stellant FLEX CT Injection System in Contrast Enhanced Mammography (CEM)

INDIANOLA, Pa., Dec. 19, 2019 /PRNewswire/ -- Bayer announced today the company received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to expand the indication of its MEDRAD ® ...
FiercePharma

FDA approves Bayer's Gadavist® (gadobutrol) injection as the first magnetic resonance contrast agent for pediatric patients less than 2 years of age

Expanded use of Gadavist is specific to detecting and visualizing areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in pediatric patients under the age ...
FiercePharma

Bayer's gadavist injection gets FDA approval as MRI contrast agent

Bayer HealthCare has received approval from the US Food and Drug Administration (FDA) for a new indication for Gadavist (gadobutrol) injection for intravenous use with MRI of the breast to assess the ...
TCTMD

FDA approves Bayer's Gadavist® (gadobutrol) injection as first contrast agent for use with magnetic resonance angiography of supra-aortic arteries

WHIPPANY, N.J., Bayer announced today that the U.S. Food and Drug Administration (FDA) has approved Gadavist ® (gadobutrol) injection for use with magnetic resonance angiography (MRA) to evaluate ...
TCTMD

FDA approves Bayer's Gadavist® (gadobutrol) injection as the first and only contrast agent for use in cardiac MR in adult patients with known or suspected coronary artery disease

WHIPPANY, N.J. - Bayer announced today the U.S. Food and Drug Administration (FDA) has approved Gadavist® (gadobutrol) injection for use in cardiac magnetic resonance (MR) imaging to assess myocardial ...
Business Wire

Global Contrast Injectors Market 2020-2024 | Evolving Opportunities with Bayer AG and Bracco Spa | Technavio

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the global contrast injectors market since 2015 and the market is poised to grow by USD 613.47 million during 2020-2024, progressing at a CAGR of ...
Stockhouse

FDA approves Bayer's Ultravist® (iopromide) injection for contrast-enhanced mammography

Ultravist™-300, -370 is now the only contrast agent in the U.S. indicated to visualize known or suspected lesions of the breast in adults, as an adjunct to mammography and/or ultrasound ...
Yahoo Finance

Bayer’s MEDRAD® Centargo Multi-Patient CT Injection System Now With A Wider Range of Compatible CT Contrast Agents and Presentations

Follows recent FDA clearance to expand the use of compatible contrast agent presentations, adding single-dose vials in addition to Imaging Bulk Package presentations Radiology suites now have the ...
Nasdaq

Bayer’s MEDRAD® Centargo Multi-Patient CT Injection System Now With A Wider Range of Compatible CT Contrast Agents and Presentations

Centargo compatible with Ultravist® (iopromide), Isovue® (iopamidol), Optiray® (ioversol), Omnipaque™ (iohexol) and now, Visipaque™ (iodixanol) Follows recent FDA clearance to expand the use of ...